Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Andro Not Within "Anabolic Steroid" Definition, Prop 65 Defendants Say

This article was originally published in The Tan Sheet

Executive Summary

Negotiations are underway between the California attorney general and 35 androstenedione supplement manufacturers and marketers aimed at resolving a Proposition 65 lawsuit filed by the state Aug. 15.
Advertisement

Related Content

Are Designer Steroids Dietary Ingredients? FDA Warning Letter Skirts Issue
Are Designer Steroids Dietary Ingredients? FDA Warning Letter Skirts Issue
Are Designer Steroids Dietary Ingredients? FDA Warning Letter Skirts Issue
Prop 65 Steroid Suit Planned Against Supplements Named In Post
Prop 65 Steroid Suit Planned Against Supplements Named In Post
Prop 65 Steroid Suit Planned Against Supplements Named In Post
Prop 65 Andro Litigation Could Include Mini-Trial On Anabolic Steroid Status
Weider Nutrition Eyes Mexico, South America For Growth Opportunities
Androstenedione
Androstenedione

Topics

Advertisement
UsernamePublicRestriction

Register

PS092945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel